



02-27-06

PCT

IAP6 Rec'd PCT/PTO 24 FEB 2006

Express Mail No.: EV 452 776 895 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Margetts <i>et al.</i>	Confirmation No.	TBA
Serial No.	10/553,111	Art Unit:	TBA
Filed:	October 12, 2005	Examiner:	TBA
For:	USE OF STEROID DERIVATIVES FOR THE TREATMENT OF ANGIOTENSIN II RELATED DISEASE E.G. CARDIOVASCULAR AND PROLIFERATIVE DISORDERS	Attorney Docket No.:	10103-030-999 (CAM No.: 052922-999030)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97**

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all information coming to the attention of each individual associated with the filing and prosecution of the above-identified application that is or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A14**, **B01-B14** and **C01-C83**, which are listed on the accompanying Substitute For Form 1449/PTO entitled "Information Disclosure Statement By Applicant."

Copies of references **B01-B14** and **C01-C83** are submitted herewith. Copies of References **A01-A06**, which are either United States patents or patent application publications, are not being submitted pursuant to 37 C.F.R. § 1.98(a)(2)(ii), unless requested by the Office.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached Substitute for Form 1449/PTO, and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*  
*By: Michael J. Bruner, Reg. No. 47,458*

Date: February 24, 2006

---

By: Michael J. Bruner (Reg. No. 47,458)  
For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(858) 314-1130

Enclosures

Substitute for Form 1449/PTO	ATTY DOCKET NO. 10103-030-999 (CAM No. 052922-999030)	APPLICATION NO. 10/553,111
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	
	APPLICANT: Margetts et al.	FILING DATE: October 12, 2005
		ART UNIT:    CONF. NO.:

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	3,296,255	01/03/1967	Clinton et al.	
	A02	3,296,295	01/03/1967	Principe et al.	
	A03	4,029,776	06/14/1977	Cafruny et al.	
	A04	4,062,954	12/13/1977	Potts	
	A05	4,196,188	04/01/1980	Besins	
	A06	4,605,517	08/12/1986	Riley et al.	
	A07	4,717,569	01/05/1988	Harrison et al.	
	A08	4,755,595	07/05/1988	Gelotte et al.	
	A09	5,372,996	12/13/1994	Labrie	
	A10	5,550,107	08/27/1996	Labrie	
	A11	5,795,881	08/18/1998	Elger et al.	
	A12	2001/0008632 A1	07/19/2001	Freund et al.	
	A13	2002/0055512	05/09/2002	Marin et al.	
	A14	2003/0050291	03/13/2003	Arad	

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01	GB 1 123 770	08/14/1968	Sterling Drug Inc.			
	B02	GB 2 010 278	06/27/1979	Sterling Drug Inc.			
	B03	GB 2 130 588	06/06/1984	Sterwin AG			
	B04	GB 2 155 018	09/18/1985	Sterwin AG			
	B05	GB 2 345 851	07/26/2000	Vinson et al.			
	B06	EP 0 072 894	03/02/1983	Sterling Drug Inc.			
	B07	EP 0 108 606	05/22/1985	Sterwin AG			
	B08	EP 0 142 309	10/29/1984	Sterwin AG			

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use several sheets if necessary)ATTY DOCKET NO.  
10103-030-999  
(CAM No. 052922-999030)APPLICATION NO.  
10/553,111APPLICANT:  
Margetts et al.FILING DATE:  
October 12, 2005

ART UNIT: CONF. NO.:

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B09	EP 0 154 476	09/11/1985	Sterwin AG			
	B10	EP 0 296 097	12/21/1988	Schering Aktiengesellschaft (w/ English abstract)			
	B11	WO 01/52833	07/26/2001	Cortendo AB			
	B12	WO 01/87334	11/22/2001	Pharmacia & Upjohn SPA			
	B13	WO 02/05791	01/24/2002	Pharmacia & Upjohn SPA			
	B14	WO 02/30429	04/18/2002	Biomedicines, Inc.			

EXAMINER'S INITIALS*	NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published, etc.)						
	C01	ALIVIZATOS et al., 1993, "Update of hormonal treatment in cancer of the prostate," Anticancer Drugs, 4(3):301-9					
	C02	ARMANINI et al. 1998, "Regulation of corticosteroid receptors in patients with anorexia nervosa and Cushing's syndrome," J Endocrinol, 158(3):435-9					
	C03	BAKER et al., 1992, "Oestrogen receptor isoforms, their distribution and relation to progesterone receptor levels in breast cancer samples," Br J Cancer, 66(6):1083-7					
	C04	BEARDWELL et al., 1983, "Trilostane in the treatment of advanced breast cancer," Cancer Chemother Pharmacol, 10(3):158-60					
	C05	BRADDOCK et al., 2002, "Trilostane and selciglene evaluated for management of pituitary-dependent hyperadrenocorticism in dogs," BSAVA Congress Sci Proc:587					
	C06	CHRISTIANSEN et al., 1984, "Steroidogenesis inhibitors. 1. Adrenal inhibitory and interceptive activity of trilostane and related compounds," J Med Chem, 27(7):928-31					
	C07	COOMBES et al., 1985, "Trilostane therapy for advanced breast cancer," Cancer Treat Rep, 69(4):351-4					
	C08	DEWIS et al., 1983, "Experience with trilostane in the treatment of Cushing's syndrome," Clin Endocrinol (Oxf), 18(6):533-40					
	C09	DOWSETT et al., 1984, "Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer," Br J Cancer, 50(3):357-361					
	C10	EASTWOOD et al., 2003, "Trilostane treatment of a dog with functional adrenocortical neoplasia," J Small Anim Pract, 44(3):126-31 Trilostane treatment of four dogs with functional adrenocortical neoplasia," J Anim Pract, 2003, 44:126-31					
	C11	FISHER et al., 1998, "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study," J Natl Cancer Inst, 90(18):1371-88					
	C12	GELDOF et al., 1995, "Inhibition of 3 beta hydroxysteroid dehydrogenase: an approach for prostate cancer treatment?," Anticancer Res, 15(4):1349-54					
	C13	HALL et al., 1999, "The estrogen receptor beta isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens," Endocrinology, 140(12):5566-78					
	C14	HARDING et al., 1984, "Inhibition of furosemide-induced kaliuresis in the rat by trilostane, an inhibitor of adrenal steroidogenesis," Proc Soc Exp Biol Med, 177(3):388-91					

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO	ATTY DOCKET NO. 10103-030-999 (CAM No. 052922-999030)	APPLICATION NO. 10/553,111
	APPLICANT: Margetts et al.	
	FILING DATE: October 12, 2005	ART UNIT:    CONF. NO.:

EXAMINER'S INITIALS*	NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published, etc.)
	C15 HARMSSEN et al., 1988, "Endocrine therapy of breast cancer," Eur J Cancer Clin Oncol, 24(7):1099-116.
	C16 HAYASHI et al., "Anti-tumor effect of Trilostane (MWD-18) for breast cancer," Nippon Gan Chiryo Gakkai Shi, 24:458 (1989) (English language abstract)
	C17 HINDLEY et al., 1984, "A comparison of two doses of trilostane combined with dexamethasone in metastatic breast cancer," Proceedings of BACR 25 <sup>th</sup> AGM:252
	C18 HOLLIFIELD et al., 1975, "Renin-secreting clear cell carcinoma of the kidney," Arch Intern Med, 135(6):859-64.
	C19 HUIZENGA et al., 2000, "Decreased ligand affinity rather than glucocorticoid receptor down-regulation in patients with endogenous Cushing's syndrome," Eur J Endocrinol, 142(5):472-6
	C20 HURLEY, 2001, "Use of trilostane for treatment of canine hyperadrenocorticism" (Poster)
	C21 HURLEY, 1998, "Trilostane in the treatment of canine hyperadrenocorticism," ESVIM, Vienna, ESVIM Newsletter, 9(2) 1999:11 (Poster)
	C22 IINO et al., 1989, "Effects of trilostane on 7,12-dimethylbenz[a]anthracene-induced rat mammary cancers and body weight of rats in relation to estrogen receptors," Oncology, 46(5):301-5
	C23 INGLE et al., 1990, "Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure," Am J Clin Oncol, 13(2):93-7
	C24 KALMIJN et al., 1998, "A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly," J Clin Endocrinol Metab, 83(10):3487-92
	C25 KIRK et al., 2000, "Cushing's disease: clinical manifestations and diagnostic evaluation," Am Fam Physician, 62(5):1119-27, 1133-4
	C26 KUMAR and CLARK, 2004, (eds), Clinical Medicine Ch. 16:815
	C27 KOMANICKY et al., 1978, "Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis," J Clin Endocrinol Metab, 47(5):1042-51
	C28 KREGE et al., 1998, "Generation and reproductive phenotypes of mice lacking estrogen receptor beta," Proc Natl Acad Sci USA, 95(26):15677-82
	C29 KUIPER et al., 1996, "Cloning of a novel receptor expressed in rat prostate and ovary," Proc Natl Acad Sci USA, 93(12):5925-30
	C30 LEE et al., 1999, "Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal stud.," Eur J Heart Fail, 1(4):401-6
	C31 LOREN, 1983, "Aztreonam," Drugs of the Future, 8:294-300
	C32 LUPIN et al., 1996, "Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups," Neurobiol Aging, 17(1):95-105
	C33 MANTIS et al., 2003, "Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane," Vet Radiol Ultrasound, 44(6):682-5
	C34 MARSIGLIANTE et al., 1991, "Significance of the 8S complex in oestrogen receptor recognition," J Steroid Biochem Mol Biol, 39(5A):703-11
	C35 MARUYAMA et al., 1998, "A novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regulator of estrogen action," Biochem Biophys Res Commun, 246(1):142-7
	C36 MCGOWAN et al., 2003, "Efficacy of trilostane for the treatment of equine Cushing's syndrome," Equine Vet J, 35(4):414-8 (Accepted Manuscript submitted)
	C37 MCGOWAN et al., 2001, "Efficacy of trilostane in the management of equine Cushing's disease," J Vet Intern Med, 15: 322, ACVIM Abstracts, 202
	C38 MCGOWAN, 2001, "Efficacy of trilostane for the treatment of equine Cushing's disease," (Poster)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449/P TO	ATTY DOCKET NO. 10103-030-999 (CAM No. 052922-999030)	APPLICATION NO. 10/553,111
	APPLICANT: Margetts et al.	
	FILING DATE: October 12, 2005	ART UNIT:    CONF. NO.:

EXAMINER'S INITIALS*	NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published, etc.)
C39	McINNES et al., 1982, "Bioavailability and pharmacological activity of micronized and nonmicronized spironolactone in healthy men, Chemical Abstracts, 96(5):87 from Congr Eur Biopharm Pharmacokinetics, 1981, 1:212-21
C40	MILCU et al., 1978, "Cortisol circadian rhythm in 70-100-year-old subjects," Endocrinologie, 16(1):29-39
C41	NEIGER et al., 2000, "Long term efficacy and safety of trilostane for treatment of canine hyperadrenocorticism," J Vet Int Med, 14:376
C42	NEIGER et al., 2001, "24 hour cortisol values in dogs with hyperadrenocorticism on trilostane," BSAVA Congress (Poster)
C43	NEIGER et al., 2002, "Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism," Vet Rec, 150(26):799-804
C44	NEIGER et al., 2003, "Owner's perceptions of trilostane therapy for hyperadrenocorticism," BSAVA Congress Sci Proc:526
C45	NEIGER, 2003, "Treatment of canine hyperadrenocorticism (Cushing's disease) with Trilostane," UK Vet 8(2)
C46	NISHIZAWA et al., 1999, "What can predict postoperative 'endocrinological cure' in Cushing's disease?," Neurosurgery, 45(2):239-44
C47	OAKLEY et al., 1997, Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor, Endocrinology, 138(11):5028-38
C48	OAKLEY et al., 1999, "The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action," J Biol Chem, 274(39):27857-66
C49	OVEREND, 2003, "Canine Cushing's syndrome: a case report," Vet Rev:21-4
C50	PACE et al., 1997, "Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha," J Biol Chem, 272(41):25832-8
C51	PAECH et al., 1997, "Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites," Science, 5:277(5331):1508-10
C52	PETERSEN et al., 1998, "Identification of estrogen receptor beta2, a functional variant of estrogen receptor beta expressed in normal rat tissues," Endocrinology, 139(3):1082-92
C53	PETRUS et al., 2003, "Use of trilostane for the treatment of pituitary-dependent hyperadrenocorticism in a cat," J Small Anim Pract, 44(6):269-72
C54	PINTO et al., 1995, "Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses," Clin Exp Hypertens, 17(3):441-68
C55	POTTS et al., 1978, "Trilostane, an orally active inhibitor of steroid biosynthesis," Steroids, 32(2):257-67
C56	PUDDEFOOT et al., 2002, "Non-competitive steroid inhibition of oestrogen receptor functions," Int J Cancer, 101(1):17-22
C57	RAMSEY et al., 2001, "The effect of trilostane on ACTH stimulation tests performed at two different timed post treatment," Proc ESVIM Congress:184-5
C58	RIGG et al., 1978, "Efficacy of intravaginal and intranasal administration of micronized estradiol-17beta," Chemical Abstracts, 88(11):69-70 from J Clin Endocrinol Metab, 1977, 45(6):1261-4
C59	ROCHA et al., 2002, "Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart," Endocrinology, 143(12):4828-36
C60	ROUSSEAU et al., 2002, "Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy," J Am Coll Cardiol, 40(9):1596-601
C61	RUBENS et al., 1991, "Treatment of metastatic breast cancer and its complications," Curr Opin Oncol, 3(6):1029-34
C62	RUCKSTUHL NS et al., 2001, "Clinical, laboratory and ultrasonographic findings in dogs with pituitary-dependent hyperadrenocorticism during trilostane treatment," Proc ESVIM Congress:140
C63	RUCKSTUHL NS et al., 2002, "Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane," Am J Vet Res, 63(4):506-12

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449/PTO	ATTY DOCKET NO. 10103-030-999 (CAM No. 052922-999030)	APPLICATION NO. 10/553,111
	APPLICANT: Margetts et al.	
	FILING DATE: October 12, 2005	ART UNIT:    CONF. NO.:

EXAMINER'S INITIALS*	NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published, etc.)
C64	SCHEINBAUM et al., 1981, "Trilostane in hyperadrenocortical states: a summary of clinical studies in the United States," Clin Pharm and Therapeutics, 29:281
C65	SCHMID et al., 2003, "Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6," J Clin Oncol, 21(6):984-90
C66	SCHREIBER et al., 1989, "Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells," Nucleic Acids Res, 17(15):6419
C67	SMITH et al., 1983, "Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer," Br Med J (Clin Res Ed), 286(6378):1615-6
C68	STARKMAN et al., 1992, "Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome," Biol Psychiatry, 32(9):756-65
C69	SUZUKI et al., 2002, "Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure," Circulation, 106(23):2967-72
C70	TAKAHASHI et al., 1990, "Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5-4 ene-isomerase activity," J Steroid Biochem Mol Biol, 37(2):231-6
C71	TOUEINI et al., 1986, "[Optimal hormonal combination for therapy of advanced breast cancer. New therapeutical approach?]" Louvain Medical, 105(2):111-120 (in French, w/ English Abstract on page 119)
C72	TUENI et al., 1987, "Endocrine effects of trilostane: in vitro and in vivo studies," Eur J Cancer Clin Oncol, 23(10):1461-7
C73	VAN CAUTER E et al., 1996, "Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol," J Clin Endocrinol Metab, 81(7):2468-73
C74	WILKINSON et al., 1986, "Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response," Cancer Res, 46(9):4862-5
C75	WILLIAMS et al., 1987, "Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer," Cancer Treat Rep, 71(12):1197-201
C76	WILLIAMS et al., 1993, "Multicenter cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer," Br J Cancer, 68(6):1210-5
C77	WITT et al., 2004, "Adrenocorticotrophic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy," Vet Rec, 154(13):399-400
C78	YAMAGUCHI Y et al., 1998, "Reduced serum dehydroepiandrosterone levels on diabetic patients with hyperinsulinaemia," Clin Endocrinol (Oxf), 49(3):377-83
C79	"Trilostane for Cushing's syndrome," 1985, Med Lett Drugs Ther, 27(698):87-8 (no authors listed)
C80	"Trilostane," Drugs of the Future, 1981, 8:494-5 (no authors listed)
C81	BEARDWELL et al., 1985, "Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone," Clin Endocrinol (Oxf), 23(4):413-21
C82	ENGELHARDT et al., 1994, "Therapy of Cushing's syndrome with steroid biosynthesis inhibitors," J Steroid Biochem Mol Biol, 49(4-6):261-7
C83	YAMAKADO et al., 1985, "Sites of action of beta-melanocyte stimulating hormone in aldosterone biosynthesis in the rat," Proc Soc Exp Biol Med, 179(3):318-23

EXAMINER	/Samira Jean-louis/	DATE CONSIDERED	07/06/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			